Does reduced MATE1 (SLC47A1) activity raise serum creatinine without lowering true GFR?

The transport protein MATE1 (Multidrug and Toxin Extrusion 1), encoded by the SLC47A1 gene, is a critical mediator of renal creatinine handling. Research confirms that reducing its activity leads to a specific physiological phenomenon known as "pseudo-renal failure," characterized by elevated serum biomarkers in the absence of true kidney damage.

Clinical and effectiveness evidence

In human physiology, approximately 10% to 40% of renal creatinine clearance is attributed to active tubular secretion rather than glomerular filtration. Clinical studies demonstrate that when MATE1 activity is compromised, this secretory component is significantly blunted:

• Pharmacological inhibition: Drugs such as cimetidine, trimethoprim, and certain antiretrovirals (e.g., dolutegravir) or kinase inhibitors (e.g., crizotinib) inhibit MATE1. These agents typically cause a 10% to 35% increase in serum creatinine levels.
• Discordance with true GFR: Gold-standard measurements of kidney function, such as inulin or iohexol clearance, remain stable in these patients despite the rising creatinine. For example, studies on MATE1 inhibitors show significant elevations in serum creatinine while the "true" Glomerular Filtration Rate (mGFR) remains unchanged (p > 0.05).
• Genetic influence: Polymorphisms in the SLC47A1 gene (e.g., the rs2289669 variant) are associated with baseline variations in serum creatinine concentrations across populations, reflecting individual differences in secretory capacity.

Mechanistic explanations

The elevation of serum creatinine occurs through a localized blockage of the renal exit pathway:

• Two-step secretion: Creatinine enters proximal tubule cells from the blood via the OCT2 (Organic Cation Transporter 2) protein on the basolateral membrane and is then pumped into the urine by MATE1 on the apical (luminal) membrane.
• Selective inhibition: When MATE1 is inhibited, creatinine accumulates within the tubule cells and subsequently the systemic circulation.
• Glomerular independence: MATE1 is located exclusively in the tubules and has no influence on the hydrostatic pressure or permeability of the glomerulus. Therefore, the rate at which fluid is filtered across the glomerular basement membrane is physically unaffected by the transporter's status.

Clinical implications

For clinicians and patients, this mechanism is highly significant for the interpretation of lab results:

• Diagnostic misinterpretation: Because most clinical equations (like CKD-EPI) estimate kidney function based solely on creatinine, MATE1 inhibition can lead to an artificially low estimated GFR (eGFR), potentially resulting in inappropriate drug dosing or unnecessary concern regarding acute kidney injury (AKI).
• Alternative markers: In cases of suspected MATE1-related creatinine elevation, using Cystatin C is recommended, as it is filtered by the glomerulus but not handled by the MATE1 tubular secretion pathway.

Bottom line

Reduced MATE1 activity elevates serum creatinine by selectively blocking its tubular secretion path. This creates a rise in serum creatinine that does not reflect a fall in true GFR, representing a change in biomarker handling rather than a change in kidney function.